2014 Acquisition Blogging Pricing 
Tech Zulu Event
MARCH 25, 2014
As we know, long gone are the days of experiencing SXSW Interactive with just 9,000 other tech entrepreneurs and business brights – with 30,000 registrants in 2013 and the final numbers for 2014 still in the works. Erin Chase – Favado , combining price comparisons with grocery shopping.
Xconomy
JULY 7, 2016
Pernix Therapeutics is slashing its headcount by more than 20 percent as the specialty pharmaceutical company tries to move toward profitability after a streak of acquisitions. In 2014, Pernix, then based in The Woodlands, TX, acquired San Diego-based Somaxon Pharmaceuticals. Those acquisitions helped Pernix reach $175.8
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Both Sides of the Table
SEPTEMBER 28, 2014
I was reading Danielle Morrill’s blog post today on whether one’s “ Startup Burn Rate is Normal. by Michael Woolf that is worth any startup founder reading to get a sense of perspective on the reality warp that is startup world during a frothy market such as 1997-1999, 2005-2007 or 2012-2014. Profitability.
Xconomy
JUNE 3, 2016
But billions of dollars in acquisitions will be left by the side of the road. Merck also saw some expected fruits of its 2014 big-ticket acquisition of Cubist Pharmaceuticals wither away this week, as the Supreme Court wouldn’t reverse a decision that shaved years off the patent life of the top-selling antibiotic daptomyicin (Cubicin).
Xconomy
SEPTEMBER 7, 2016
After in-licensing and developing multiple other compounds and taking the company public through a reverse merger, Shkreli was ousted from Retrophin in late 2014—shortly after he raised the price on an old drug used for treating a condition related to kidney stones, which the company acquired, from $1.50 to $30 apiece.
Xconomy
JULY 1, 2016
At the gathering, Biden took verbal shots at scofflaw cancer researchers and at drug prices, while the FDA said it would take a shot at restructuring the way it evaluates oncology products. Gilead Sciences has been a target of drug-price criticism for its hepatitis C treatments, but it dialed back the price of its new one.
Xconomy
JULY 18, 2016
In early trading Monday, Evoke’s (NASDAQ: EVOK ) stock price was down 72 percent to $3.02 Originally developed by Rhythm Pharmaceuticals, the drug aimed to cut patients’ gastric emptying time—how long it takes for the stomach to flush out food—and showed positive results during a Phase 2 trial in May 2014. in New York.
Expert insights. Personalized for you.
99 
Let's personalize your content